Literature DB >> 25824420

Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible?

Arya Amini1, David C Westerly1, Timothy V Waxweiler1, Nicole Ryan1, David Raben2.   

Abstract

Targeted focal therapy strategies for treating single-lobe prostate cancer are under investigation. In this planning study, we investigate the feasibility of treating a portion of the prostate to full-dose external beam radiation with reduced dose to the opposite lobe, compared with full-dose radiation delivered to the entire gland using hypofractionated radiation. For 10 consecutive patients with low- to intermediate-risk prostate cancer, 2 hypofractionated, single-arc volumetric-modulated arc therapy (VMAT) plans were designed. The first plan (standard hypofractionation regimen [STD]) included the entire prostate gland, treated to 70 Gy delivered in 28 fractions. The second dose painting plan (DP) encompassed the involved lobe treated to 70 Gy delivered in 28 fractions, whereas the opposing, uninvolved lobe received 50.4 Gy in 28 fractions. Mean dose to the opposing neurovascular bundle (NVB) was considerably lower for DP vs STD, with a mean dose of 53.9 vs 72.3 Gy (p < 0.001). Mean penile bulb dose was 18.6 Gy for DP vs 19.2 Gy for STD (p = 0.880). Mean rectal dose was 21.0 Gy for DP vs 22.8 Gy for STD (p = 0.356). Rectum V70 (the volume receiving ≥70 Gy) was 2.01% for DP vs 2.74% for STD (p = 0.328). Bladder V70 was 1.69% for DP vs 2.78% for STD (p = 0.232). Planning target volume (PTV) maximum dose points were 76.5 and 76.3 Gy for DP and STD, respectively (p = 0.760). This study demonstrates the feasibility of using VMAT for partial-lobe prostate radiation in patients with prostate cancer involving 1 lobe. Partial-lobe prostate plans appeared to spare adjacent critical structures including the opposite NVB.
Copyright © 2015 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dose painting; Low risk; Morbidity; Prostate cancer; Targeted focal therapy

Mesh:

Year:  2015        PMID: 25824420     DOI: 10.1016/j.meddos.2015.02.002

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  4 in total

1.  Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.

Authors:  Amar U Kishan; Sang J Park; Christopher R King; Kristofer Roberts; Patrick A Kupelian; Michael L Steinberg; Mitchell Kamrava
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

2.  Reproducibility in contouring the neurovascular bundle for prostate cancer radiation therapy.

Authors:  Richard J Cassidy; Sherif G Nour; Tian Liu; Jeffrey M Switchenko; Sibo Tian; Matthew J Ferris; Robert H Press; Jim Zhong; Mustafa Abugideiri; Peter J Rossi; Ashesh B Jani
Journal:  Pract Radiat Oncol       Date:  2017-08-03

3.  Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy.

Authors:  Ulrika Björeland; Tufve Nyholm; Joakim Jonsson; Mikael Skorpil; Lennart Blomqvist; Sara Strandberg; Katrine Riklund; Lars Beckman; Camilla Thellenberg-Karlsson
Journal:  Phys Imaging Radiat Oncol       Date:  2021-02-24

4.  Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning.

Authors:  Elisha Fredman; Bryan Traughber; Michael Kharouta; Tarun Podder; Simon Lo; Lee Ponsky; Gregory MacLennan; Raj Paspulati; Bradley Ellis; Mitchell Machtay; Rodney Ellis
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.